➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Moodys
McKinsey
Medtronic
Johnson and Johnson
AstraZeneca

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

DELESTROGEN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Delestrogen, and when can generic versions of Delestrogen launch?

Delestrogen is a drug marketed by Par Sterile Products and is included in one NDA.

The generic ingredient in DELESTROGEN is estradiol valerate. There are seventy-five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the estradiol valerate profile page.

US ANDA Litigation and Generic Entry Outlook for Delestrogen

A generic version of DELESTROGEN was approved as estradiol valerate by AM REGENT on January 19th, 2010.

  Start Trial

US Patents and Regulatory Information for DELESTROGEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Par Sterile Products DELESTROGEN estradiol valerate INJECTABLE;INJECTION 009402-002 Approved Prior to Jan 1, 1982 AO RX Yes Yes   Start Trial   Start Trial   Start Trial
Par Sterile Products DELESTROGEN estradiol valerate INJECTABLE;INJECTION 009402-004 Approved Prior to Jan 1, 1982 AO RX Yes Yes   Start Trial   Start Trial   Start Trial
Par Sterile Products DELESTROGEN estradiol valerate INJECTABLE;INJECTION 009402-003 Approved Prior to Jan 1, 1982 AO RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Merck
Dow
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.